Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 4.2
-3.45 %
$ 4.04 M
Market Cap
-0.23
P/E
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.[ Read More ]
The intrinsic value of one ISPC stock under the base case scenario is HIDDEN Compared to the current market price of 4.2 USD, iSpecimen Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart ISPC
FINANCIALS
9.93 M
REVENUE
-11.2 M
OPERATING INCOME
-11.1 M
NET INCOME
-5.81 M
OPERATING CASH FLOW
-7.23 M
INVESTING CASH FLOW
70.9 K
FINANCING CASH FLOW
2.66 M
REVENUE
-1.71 M
OPERATING INCOME
-1.44 M
NET INCOME
-1.08 M
OPERATING CASH FLOW
-180 K
INVESTING CASH FLOW
860 K
FINANCING CASH FLOW
Balance Sheet Decomposition
iSpecimen Inc.
| Current Assets | 8.24 M |
| Cash & Short-Term Investments | 5.01 M |
| Receivables | 2.94 M |
| Other Current Assets | 292 K |
| Non-Current Assets | 7.58 M |
| Long-Term Investments | 0 |
| PP&E | 322 K |
| Other Non-Current Assets | 7.26 M |
| Current Liabilities | 6.05 M |
| Accounts Payable | 3.93 M |
| Short-Term Debt | 334 K |
| Other Current Liabilities | 1.79 M |
| Non-Current Liabilities | 29.1 K |
| Long-Term Debt | 29.1 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
iSpecimen Inc.
| Revenue | 9.93 M |
| Cost Of Revenue | 4.82 M |
| Gross Profit | 5.11 M |
| Operating Expenses | 16.3 M |
| Operating Income | -11.2 M |
| Other Expenses | -69.9 K |
| Net Income | -11.1 M |
RATIOS
51.45%
GROSS MARGIN
-112.50%
OPERATING MARGIN
-111.80%
NET MARGIN
-113.95%
ROE
-70.16%
ROA
-112.73%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
iSpecimen Inc.
| Net Income | -11.1 M |
| Depreciation & Amortization | 2.12 M |
| Capital Expenditures | -4.74 M |
| Stock-Based Compensation | 460 K |
| Change in Working Capital | 2.59 M |
| Others | 430 K |
| Free Cash Flow | -10.6 M |
Wall Street Analysts Price Targets
iSpecimen Inc.
ISPC has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
iSpecimen Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Sep 14, 2023
|
Bought 13 K USD
|
Bielak Benjamin
Chief Info Officer & Secretary |
+ 18000
|
0.72 USD |
|
1 year ago
May 31, 2023
|
Bought 5.5 K USD
|
Curley Tracy
CEO, CFO and Treasurer |
+ 4400
|
1.25 USD |
|
3 years ago
Nov 16, 2021
|
Bought 5.19 K USD
|
Ross Andrew L.
director, 10 percent owner: |
+ 1000
|
5.19 USD |
|
3 years ago
Nov 15, 2021
|
Bought 2.65 K USD
|
Ross Andrew L.
director, 10 percent owner: |
+ 500
|
5.3 USD |
|
3 years ago
Nov 15, 2021
|
Bought 2.64 K USD
|
Ross Andrew L.
director, 10 percent owner: |
+ 500
|
5.29 USD |
|
3 years ago
Nov 10, 2021
|
Bought 2.92 K USD
|
Ross Andrew L.
director, 10 percent owner: |
+ 500
|
5.85 USD |
|
3 years ago
Nov 08, 2021
|
Bought 5.73 K USD
|
Ross Andrew L.
director, 10 percent owner: |
+ 1000
|
5.73 USD |
|
3 years ago
Jun 23, 2021
|
Bought 2.61 K USD
|
Ross Andrew L.
director, 10 percent owner: |
+ 400
|
6.52 USD |
|
3 years ago
Jun 17, 2021
|
Bought 627 USD
|
Ross Andrew L.
director, 10 percent owner: |
+ 100
|
6.27 USD |
|
3 years ago
Nov 17, 2021
|
Bought 10.2 K USD
|
Curley Tracy
Chief Financial Officer |
+ 2000
|
5.12 USD |
|
3 years ago
Nov 16, 2021
|
Bought 41.8 K USD
|
Curley Tracy
Chief Financial Officer |
+ 8000
|
5.23 USD |
7. News
iSpecimen Named Top Competitor in $4.4 Billion USD Market
Biospecimen Market To Exceed $13.5 Billion USD By 2032 Woburn, Massachusetts--(Newsfile Corp. - November 8, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the addressable Biospecimen contract research services market is attractive and growing. In fact, according to AceInsight Analytic, the market is presently valued at USD 4.4 billion as of 2023 and is predicted to reach USD 13.5 billion by the year 2032, growing at a 13.3% CAGR during the forecast period.
newsfilecorp.com
- 1 week ago
iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually
WOBURN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today a significant enhancement to its searchable inventory that provides researchers with increased access to a wide array of biospecimens vital to advancing oncology research and treatments.
globenewswire.com
- 1 week ago
iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced public offering of approximately $5 million of the Company's common stock and pre-funded warrants to purchase shares of common stock at a public offering price of $3.00 per share (minus $0.0001 per pre-funded warrant). The Company intends to use the proceeds of the offering for repayment of outstanding debt, potential acquisitions of assets or investments in businesses, products and technologies and for marketing and advertising services. The remainder of the proceeds will be used for working capital purposes.
globenewswire.com
- 2 weeks ago
iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
WOBURN, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the pricing of its public offering of approximately $5 million of the Company's common stock, and/or pre-funded warrants to purchase shares of common stock at a public offering price of $3.00 per share (minus $0.0001 per pre-funded warrant). The Company intends to use the proceeds of the offering for repayment of outstanding debt, potential acquisitions of assets or investments in businesses, products and technologies and for marketing and advertising services. The remainder of proceeds will be used for working capital purposes.
globenewswire.com
- 2 weeks ago
iSpecimen Secures $1 Million Loan; Appoints Three New Board Members
WOBURN, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it has secured a $1 million loan agreement and subsequently appointed three new members to its Board of Directors.
globenewswire.com
- 1 month ago
iSpecimen Announces 1-for-20 Reverse Stock Split
WOBURN, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it will effect a reverse stock split of its issued and outstanding shares of common stock, par value $0.0001 per share, as well as any shares of common stock held by the Company in treasury, at a ratio of 1-for-20. The reverse stock split will become effective at 4:30 p.m. Eastern Time on September 13, 2024, and the Company's common stock will begin trading on a split-adjusted basis when the market opens on September 16, 2024. The Company's common stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol "ISPC." The new CUSIP number for the Company's common stock following the reverse stock split will be 45032V207.
globenewswire.com
- 2 months ago
iSpecimen Inc. (ISPC) Q2 2024 Earnings Call Transcript
iSpecimen Inc. (NASDAQ:ISPC ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Phil Carlson - IR, KCSA Strategic Communications Tracy Curley - CEO and CFO Leslie Hoyt - VP, Operations Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Operator Good morning everyone and welcome to the iSpecimen Second Quarter 2024 Earnings Conference Call. At this time, participants are in a listen-only mode.
seekingalpha.com
- 3 months ago
iSpecimen Reports Second Quarter 2024 Results
Revenue increased 76% year-over-year to approximately $2.86 million Brielan Smiechowski Named SVP of Sales and Business Development LEXINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and six month periods ended June 30, 2024.
globenewswire.com
- 3 months ago
iSpecimen Inc. (ISPC) Q1 2024 Earnings Call Transcript
iSpecimen Inc. (NASDAQ:ISPC ) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Phil Carlson - Investor Relations, KCSA Strategic Communications Tracy Curley - Chief Executive Officer & Chief Financial Officer Leslie Hoyt - Senior Vice President of Operations Conference Call Participants Matt Hewitt - Craig Hallum Capital Operator Good day everyone and welcome to iSpecimen's First Quarter 2024 Results Conference Call. [Operator Instructions] This conference call is being recorded.
seekingalpha.com
- 6 months ago
iSpecimen Reports First Quarter 2024 Results
LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three-month period ended March 31, 2024.
globenewswire.com
- 6 months ago
iSpecimen to Report First Quarter 2024 Financial Results on May 7, 2024
LEXINGTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the first quarter of 2024 ended March 31, 2024 before the market opens on Tuesday, May 7, 2024.
globenewswire.com
- 6 months ago
iSpecimen Reports Full Year 2023 Results
LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the twelve-month period ended December 31, 2023.
globenewswire.com
- 8 months ago
8. Profile Summary
iSpecimen Inc. ISPC
COUNTRY
US
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 4.04 M
Dividend Yield
0.00%
Description
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Contact
450 Bedford Street, Lexington, MA, 02420
https://ispecimen.com
IPO Date
June 17, 2021
Employees
53
Officers
Ms. Brielan Smiechowski
Senior Vice President of Business Development
Ms. Tracy Wilson Curley
Chief Executive Officer, Chief Financial Officer, Treasurer & Director
Ms. Carly Lejnieks
Vice President of Marketing
Mr. Evan Cox
Senior Vice President of Strategy & Innovation
Ms. Leslie Hoyt
Senior Vice President of Operations
Ms. Annette Arnold
Vice President of Sales & Business Development